Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Icon (NASDAQ: ICLR)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (BIIBResearch Report), BioMarin Pharmaceutical (BMRNResearch Report) and Icon (ICLRResearch Report).

Biogen (BIIB)

In a report released today, Salim Syed from Mizuho Securities maintained a Hold rating on Biogen, with a price target of $244.00. The company’s shares closed last Thursday at $329.22.

According to TipRanks.com, Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.6% and a 46.1% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences.

Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $427.41, a 33.5% upside from current levels. In a report issued on July 8, Robert W. Baird also maintained a Hold rating on the stock with a $382.00 price target.

See today’s analyst top recommended stocks >>

BioMarin Pharmaceutical (BMRN)

Wedbush analyst Liana Moussatos reiterated a Buy rating on BioMarin Pharmaceutical today and set a price target of $141.00. The company’s shares closed last Thursday at $78.88, close to its 52-week low of $71.35.

According to TipRanks.com, Moussatos is a 3-star analyst with an average return of 4.0% and a 37.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Eiger Biopharmaceuticals, and Lexicon Pharmaceuticals.

Currently, the analyst consensus on BioMarin Pharmaceutical is a Strong Buy with an average price target of $109.82, representing a 38.3% upside. In a report issued on July 8, Leerink Partners also initiated coverage with a Buy rating on the stock.

Icon (ICLR)

Jefferies analyst David Windley maintained a Buy rating on Icon yesterday and set a price target of $276.00. The company’s shares closed last Thursday at $209.66.

According to TipRanks.com, Windley is a top 100 analyst with an average return of 20.4% and a 75.9% success rate. Windley covers the Healthcare sector, focusing on stocks such as Syneos Health, Catalent, and Humana.

Currently, the analyst consensus on Icon is a Moderate Buy with an average price target of $248.13, a 16.9% upside from current levels. In a report issued on July 16, Evercore ISI also maintained a Buy rating on the stock with a $285.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.